HSE approves new treatment for skin cancer patients - (The Irish Times via NewsPoints Desk)

  • Ireland's Health Service Executive has approved reimbursement for encorafenib in combination with binimetinib for the treatment of adults with unresectable or metastatic melanoma who have the BRAF V600 mutation, reported The Irish Times.

  • According to the news source, just over 1000 patients in Ireland have melanoma, with roughly half carrying the BRAF mutation. 

  • The manufacturer, Pierre Fabre, says an oral combination of the two drugs increased median progression-free survival by more than seven months relative to existing treatments.

  • The company added that the combination has also been shown to increase overall survival by 16 months versus existing treatments.

To read more NewsPoints articles, click here.

Reference Articles